Recently, the S&P Global Corporate Sustainability Assessment (CSA) successively announced the 2023 Environmental, Social, and Governance (ESG) rating results. Sino Biopharm (HK.1177) achieved a score improvement for the second consecutive year. This year, the Group's score steadily increased to 55, a 10-point improvement from the previous year, ranking in the top 9% globally for the second consecutive year.

The S&P Global Corporate Sustainability Assessment is one of the world's largest annual assessments of corporate sustainability practices. By quantifying and scoring a company's various ESG management and performance indicators, it comprehensively reflects the company's ESG management and information disclosure levels, serving as an important basis for global investors' investment decisions and data analysis. In 2023, approximately 350 pharmaceutical companies worldwide were invited to participate in the assessment. Achieving a score that surpasses 91% of its global peers for two consecutive years represents a high level of recognition from institutions for Sino Biopharm's sustainable development practices.

In terms of corporate governance, Sino Biopharm continuously enhances the professionalism, independence, and diversity of its Board of Directors, ensuring stable corporate operations through high-quality corporate governance. In recent years, Sino Biopharm has adhered to internationalized innovation and continuously increased its investment in independent R&D. Currently, the Group has entered a harvest period for its innovation achievements. In 2022, the net income from innovative drugs reached RMB 6.75 billion, a year-on-year increase of 20%. In the next three years, the Group will have nearly 10 innovative drugs launched, injecting strong momentum into long-term sustainable development. In the field of risk management, the Group fully considers and controls risks in areas such as ESG and emerging risks, and actively fosters a corporate culture of transparency and integrity.

Sino Biopharm adheres to its internationalization strategy, targeting unmet clinical needs globally. Through a synergistic approach of independent R&D and in-licensing of overseas innovative achievements, it promotes the R&D and marketing approval of more high-quality new drugs to benefit patients worldwide. At the same time, the Group promotes medical accessibility in multiple ways. On one hand, it provides patients with high-quality, affordable drugs by improving quality and efficiency; on the other hand, it further reduces the medication burden on patients by developing various public welfare and charitable activities. In the field of human development, the Group continuously creates an excellent work experience, empowers employee development, and supports the mutual growth of the company and its employees.

In 2023, Sino Biopharm was also honored with multiple awards, including an MSCI ESG A rating, inclusion in CCTV's "China ESG Listed Companies Pioneer 100", "2023 Forbes China ESG Innovative Enterprise", and the "Top 100 Chinese Overseas Listed Companies in ESG and Low-Carbon Ranking".

In the future, Sino Biopharm will uphold the concept of sustainability, continue to integrate the ESG concept with the Group's development strategy, enhance risk management levels, promote stable business growth, and create long-term value for shareholders, patients, employees, and all sectors of society.